Cemiplimab-rwlc

ImmunotherapyApproved for: NSCLC NSCLC patients tumors with high PD-L1 expression and without EGFR, ALK, ROS1 aberrations. Related Research News Pre- and Post-surgical Immunotherapy-based Treatment Significantly Improved Lung Cancer OutcomesLong-term study reveals ‘ever-changing’ nature of lung cancerLung Cancer Trial Has...
|
February 25, 2021
|